• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum.

作者信息

Kotnik Nika, Diercks Gilles F H, Jalving Hilde, Hospers Geke A P, Oosting Sjoukje F, van Kruchten Michel, Hiltermann T Jeroen N, Bolling Maria C, Bremer Jeroen, Horváth Barbara, Meijer Joost M

机构信息

Department of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the Netherlands.

Division of Experimental Allergy and Immunodermatology, University of Oldenburg, Oldenburg, Germany.

出版信息

JAAD Case Rep. 2025 Apr 4;61:100-106. doi: 10.1016/j.jdcr.2025.03.021. eCollection 2025 Jul.

DOI:10.1016/j.jdcr.2025.03.021
PMID:40538786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12176681/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/12176681/f9f96d1083ad/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/12176681/0dfe11050fb6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/12176681/f9f96d1083ad/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/12176681/0dfe11050fb6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/12176681/f9f96d1083ad/gr2.jpg

相似文献

1
Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum.类天疱疮疾病作为免疫检查点抑制剂治疗后的免疫相关不良反应：一个多样化病例系列
JAAD Case Rep. 2025 Apr 4;61:100-106. doi: 10.1016/j.jdcr.2025.03.021. eCollection 2025 Jul.
2
A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.一例继发于免疫治疗的药物性大疱性类天疱疮，使用乌帕替尼治疗：病例报告。
SAGE Open Med Case Rep. 2023 Mar 21;11:2050313X231160926. doi: 10.1177/2050313X231160926. eCollection 2023.
3
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.转移性肾细胞癌患者停用免疫检查点抑制剂后疾病持久控制且并发难治性大疱性类天疱疮：一例报告。
Front Immunol. 2022 Sep 16;13:984132. doi: 10.3389/fimmu.2022.984132. eCollection 2022.
4
A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.一例继发于检查点抑制剂免疫治疗的大疱性类天疱疮罕见病例：情况危急
Cureus. 2021 Jul 4;13(7):e16169. doi: 10.7759/cureus.16169. eCollection 2021 Jul.
5
An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis.帕博利珠单抗的双重不良影响：一例大疱性类天疱疮合并肺炎的病例报告
J Med Cases. 2025 Feb;16(2):69-76. doi: 10.14740/jmc5089. Epub 2025 Feb 2.
6
[Bullous pemphigoid induced by cancer immunotherapy].[癌症免疫疗法诱发的大疱性类天疱疮]
Rev Med Suisse. 2020 Apr 1;16(688):624-628.
7
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.
8
Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.与抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1治疗相关的大疱性类天疱疮：文献综述
Acta Derm Venereol. 2021 Jan 20;101(1):adv00377. doi: 10.2340/00015555-3740.
9
Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.两例与免疫检查点抑制剂相关的大疱性类天疱疮罕见病例。
BMJ Case Rep. 2022 Dec 7;15(12):e253059. doi: 10.1136/bcr-2022-253059.
10
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.病例报告：一位患有膀胱癌的患者出现早发性免疫介导性大疱性类天疱疮。
Curr Oncol. 2023 Aug 23;30(9):7802-7809. doi: 10.3390/curroncol30090566.

本文引用的文献

1
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.癌症患者接受免疫检查点抑制剂治疗与大疱性类天疱疮的关联：一项系统评价。
JAMA Dermatol. 2022 Aug 1;158(8):933-941. doi: 10.1001/jamadermatol.2022.1624.
2
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.抗程序性细胞死亡蛋白 1 和抗程序性细胞死亡配体 1 治疗的患者中皮肤免疫相关不良事件与生存改善相关。
JAMA Dermatol. 2022 Feb 1;158(2):189-193. doi: 10.1001/jamadermatol.2021.5476.
3
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.
抗PD-1/PD-L1治疗相关大疱性类天疱疮的临床、生物学和组织学特征：一项全国性回顾性研究。
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e511-e514. doi: 10.1111/jdv.17253. Epub 2021 Apr 13.
4
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.回顾性分析来自德国六个皮肤科中心的与检查点抑制剂治疗相关的大疱性类天疱疮病例。
Front Immunol. 2021 Feb 23;11:588582. doi: 10.3389/fimmu.2020.588582. eCollection 2020.
5
Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.与抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1治疗相关的大疱性类天疱疮：文献综述
Acta Derm Venereol. 2021 Jan 20;101(1):adv00377. doi: 10.2340/00015555-3740.
6
Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.接受检查点抑制剂治疗的黑色素瘤患者的皮肤免疫相关不良事件。
Br J Dermatol. 2021 Aug;185(2):263-271. doi: 10.1111/bjd.19750. Epub 2021 Feb 1.
7
Nonbullous pemphigoid secondary to PD-1 inhibition.PD-1抑制继发的非大疱性类天疱疮
JAAD Case Rep. 2019 Oct 3;5(10):898-903. doi: 10.1016/j.jdcr.2019.07.015. eCollection 2019 Oct.
8
Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.大疱性类天疱疮和非大疱性类天疱疮的早期识别诊断策略评估。
JAMA Dermatol. 2019 Feb 1;155(2):158-165. doi: 10.1001/jamadermatol.2018.4390.
9
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.黏膜类天疱疮、大疱性类天疱疮与抗程序性死亡蛋白1/程序性死亡配体1：1例老年女性在帕博利珠单抗治疗转移性黑色素瘤后发生黏膜类天疱疮的病例报告及文献复习
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
10
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.